Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295433 · ClinicalTrials.gov registry record · Phase 1
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
A Phase 1 study of Methylmalonic Acidemia, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 12
- Study locations
NCT05295433: Recruiting Phase 1 study of Methylmalonic Acidemia, sponsored by ModernaTX.
NCT05295433 is a Phase 1 study of Methylmalonic Acidemia that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 56 participants, below the 418-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05295433, a Phase 1 study of Methylmalonic Acidemia, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.
Conditions Studied
Interventions
- DRUG mRNA-3705
Study Locations (12)
Other
- Hôpital Necker - Enfants Malades APHP - Paris
- Erasmus MC - Rotterdam
- Universitair Medisch Centrum Utrecht - Utrecht
- Hospital Universitario 12 de Octubre - Madrid
- Birmingham Children's Hospital NHS Foundation Trust - Birmingham
- Royal Manchester Childrens Hospital - Manchester
California
- UCLA Medical Center - Los Angeles
- Lucile Packard Children's Hospital at Stanford - Palo Alto
- Altman Clinical and Translational Research Institution - San Diego
Alberta
- Stollery Children's Hospital University of Alberta - Edmonton
Ontario
- Hospital For Sick Children - Toronto
Vizcaya
- Hospital Universitario Cruces - Barakaldo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2034-04-02 |
| Phase | Phase 1 |
What NCT05295433 shows while recruiting
NCT05295433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 418-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Methylmalonic Acidemia appearing as the primary indexed condition, and to 1 intervention - of which mRNA-3705 is the first listed.
NCT05295433 lists 12 locations in 5 states (Other, California, Alberta).
Frequently Asked Questions
What is clinical trial NCT05295433 about?
NCT05295433 is a clinical study titled "An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705". The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRN...
What is the current status of trial NCT05295433?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-03-08. Estimated completion is 2034-04-02.
What conditions does trial NCT05295433 study?
This clinical trial studies the following conditions: Methylmalonic Acidemia.
What interventions are being tested in trial NCT05295433?
The interventions under investigation include: mRNA-3705 (DRUG).
Who is sponsoring clinical trial NCT05295433?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05295433 being conducted?
This trial has 12 study locations across California, Alberta, Ontario, Vizcaya. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methylmalonic Acidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
ACTIVE NOT RECRUITING · Phase 1
-
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
RECRUITING
-
Clinical and Laboratory Study of Methylmalonic Acidemia
RECRUITING
-
Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
ACTIVE NOT RECRUITING
-
"The MaP Study": Mapping the Patient Journey in MMA and PA
COMPLETED
-
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI